KYMR – kymera therapeutics, inc. (US:NASDAQ)

News

Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Morgan Stanley from $45.00 to $49.00. They now have an "equal weight" rating on the stock.
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target lowered by analysts at UBS Group AG from $80.00 to $74.00. They now have a "buy" rating on the stock.
Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com